Rutgers HOPE: Health Outcomes, Policy, & Economics Program

What Rutgers HOPE: Health Outcomes, Policy, & Economics Program does

Rutgers HOPE (Health Outcomes, Policy, and Economics) is an academic graduate program and interdisciplinary research center jointly operated by the Ernest Mario School of Pharmacy and the Rutgers School of Public Health, with affiliated faculty from the Robert Wood Johnson Medical School and the Institute for Health. It specializes in formal economic and outcome analysis of pharmaceuticals and other healthcare innovations, offering the Master of Science in Health Outcomes, Policy, and Economics (MS-HOPE), an 18-credit certificate program, and a dual PharmD-MS degree pathway that compresses completion to 7.5 years versus 8 sequential. The curriculum covers cost-effectiveness, cost-utility, and cost-benefit analysis, decision analysis, health technology assessment, experimental and quasi-experimental design, statistics, and SAS-based analytics.

The program operates multiple industry-funded post-doctoral fellowships with Johnson & Johnson (SEPR and RWVE teams), Novo Nordisk, and GSK, embedding fellows within pharmaceutical company teams for one to two years while they complete graduate coursework. A historical Allergan fellowship relationship is also noted. Research areas include aging and dementia, ocular disease, blood products, and vaccine-preventable diseases, with fellows utilizing large real-world data assets such as Medicare, Medicaid, MarketScan, CPRD, and SEER-Medicare. As of May 2022, 41 graduates had completed the program, of whom 26 entered industry roles, 3 academia, 2 healthcare providers, and 10 other pursuits including PhD programs and consulting.

The business model is tuition-funded (MS-HOPE degree, certificate program) supplemented by industry-sponsored fellowship seats. Distribution is routed through the SOPHAS graduate public health application portal, and the program is led by Director Chintan Dave, PharmD, PhD. The center is housed in Piscataway, New Jersey, and reports cumulative scale of 100+ MS students, 20+ industry fellows, and 25+ faculty. No public company exists — Rutgers HOPE is a unit within Rutgers, The State University of New Jersey, a public state university, and does not have external investors or disclosed financials.

Name

Rutgers HOPE: Health Outcomes, Policy, & Economics Program

Legal name

Center for Health Outcomes, Policy, and Economics (HOPE)

Website

https://hope.rutgers.edu

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Rutgers HOPE is an academic graduate program and research center jointly operated by the Ernest Mario School of Pharmacy and Rutgers School of Public Health, offering the MS-HOPE degree, certificates, and industry-funded fellowships with Johnson & Johnson, Novo Nordisk, and GSK. It serves students and pharma fellows seeking HEOR training.

Ownership category

akta.pro rank

Product category

Higher Education

NAICS

Colleges, Universities, and Professional Schools (6113)

SIC

Services-Health Services (8000)

akta.pro primary industry

Schools of Public Health (EDAHAGAD)

akta.pro secondary industry

Schools of Pharmacy (EDAHAGAE)

Keywords

• Health economics research
• Outcomes research training
• Pharmacoepidemiology programs
• Graduate health policy
• Pharmaceutical industry fellowships

Headquarters

HQ city

Piscataway

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Tuition and Fees: Revenue generated from student tuition for the MS-HOPE degree program and certificate programs. Additional revenue from fellowship programs funded by industry partners including Johnson & Johnson, Novo Nordisk, and GSK.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Rutgers HOPE is an academic graduate program and interdisciplinary research center that offers a Master of Science in Health Outcomes, Policy, and Economics (MS-HOPE), a certificate program, and a dual PharmD-MS degree, combined with industry-funded postdoctoral fellowships in partnership with pharmaceutical companies. It provides interdisciplinary training in health economics, outcomes research, pharmacoepidemiology, and health policy through the Ernest Mario School of Pharmacy and the Rutgers School of Public Health.

Product overview

Rutgers HOPE is an academic graduate program and interdisciplinary research initiative that offers educational programs in health economics, outcomes research, and policy. The core offering is the MS-HOPE degree program, supplemented by a certificate program and a dual PharmD-MS degree option. The program also partners with pharmaceutical companies (Novo Nordisk, Johnson & Johnson) to offer industry fellowships that provide practical training alongside academic coursework. Together, these offerings create a comprehensive pathway from academic training to careers in the pharmaceutical industry, healthcare, and academia.

Differentiator

Problem solved

Functional benefit

Products and services

• MS-HOPE (Master of Science in Health Outcomes, Policy, and Economics) A graduate degree program providing interdisciplinary training in health economics, outcomes research, pharmacoeconomics, epidemiology, and health policy to prepare students for careers in the pharmaceutical industry, healthcare, and academia.
• Certificate in Health Outcomes, Policy, and Economics An 18-credit certificate program exposing learners to foundational concepts in health economics, outcomes, and research (HEOR), designed for students considering HEOR career paths with pharmaceutical/biotech industry, health insurance payers, and government healthcare agencies.
• Dual PharmD-MS Degree Program A combined Doctor of Pharmacy and Master of Science in Health Outcomes, Policy, and Economics dual degree program allowing EMSOP pharmacy students to complete both degrees in 7.5 years instead of 8 years sequentially.
• Novo Nordisk Fellowship A two-year immersive fellowship at Novo Nordisk embedded within their Clinical Data Science and Evidence (CDSE) team, combining full-time industry research with graduate coursework toward the Rutgers MS-HOPE degree, spanning the entire RWE/HEOR evidence cycle from proposal to publication.
• J&J RWVE Fellowship (Real World Value and Evidence Solid Tumor Oncology) A one-year industry fellowship (with potential renewal for a second year) offered in partnership with Johnson & Johnson Innovative Medicine, providing hands-on experience in real-world evidence research, health economics, patient outcomes, and market access in oncology.
• J&J SEPR Fellowship (Scientific Evidence and Policy Research) A fellowship program in partnership with Johnson & Johnson Innovative Medicine's SEPR team, focusing on real-world evidence, health economics, patient outcomes, market access, and policy research to prepare fellows for evidence-based decision-making across the pharmaceutical industry.

Quantifiable outcome

• 41 students graduated as of May 2022, with 26 working in industry, 3 in academia, 2 with health providers, and 10 pursuing other endeavors
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• Johnson & Johnson Innovative Medicine - SEPR TeamcoreStrategic or Co-development PartnerThe Scientific Evidence and Policy Research (SEPR) team within Johnson & Johnson Innovative Medicine partners with Rutgers HOPE to offer a fellowship focused on real world evidence, health economics, patient outcomes, market access and policy research. The program provides interdisciplinary training through hands-on industry research, academic coursework, and professional mentorship to prepare fellows for evidence-based decision making across the pharmaceutical industry setting.
• Johnson & Johnson Innovative Medicine - RWVE TeamcoreStrategic or Co-development PartnerPartnership with the Real World Value and Evidence (RWVE) Solid Tumor Oncology team at Johnson & Johnson Innovative Medicine offers hands-on experience in real-world evidence research, health economics, patient outcomes, and market access. Fellows work with RWVE researchers to generate high-quality evidence demonstrating the value of J&J Innovative Medicine products. The program combines onsite industry research in Titusville, New Jersey with didactic coursework and professional seminars.
• Novo NordiskcoreStrategic or Co-development PartnerThe HOPE–Novo Nordisk Fellowship offers a two-year immersive fellowship at the intersection of industry and academia. Unlike traditional 1+1 HEOR models, fellows spend two full years embedded at Novo Nordisk gaining continuity and deeper ownership across the entire RWE/HEOR evidence cycle from proposal to publication. Concurrently, fellows pursue graduate coursework toward the Rutgers MS-HOPE degree.
• GSK (GlaxoSmithKline)minorStrategic or Co-development PartnerGSK-HOPE fellowships offered including both Global and U.S. variants. Alumni include Kejsi Begaj (PharmD) as GSK-HOPE Global Fellow 2023-2025 and Alin Kalayjian (PharmD, MBA) as GSK-HOPE U.S. Fellow 2023-2025.
• AllerganminorStrategic or Co-development PartnerPast fellowship partnership with Allergan. Zack Babcock (PhD) served as Allergan-HOPE Fellow 2019-2020.
• Ernest Mario School of Pharmacy and Rutgers School of Public HealthcoreStrategic or Co-development PartnerHOPE is a joint program between the Ernest Mario School of Pharmacy (EMSOP) and the School of Public Health (SPH), providing interdisciplinary training drawing on expertise from both institutions along with Robert Wood Johnson Medical School.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Johns Hopkins Bloomberg School of Public Health: Top-ranked school of public health with extensive graduate programs in health policy, epidemiology, and biostatistics. Comparable as a producer of HEOR talent and research, with much broader scale and scope than HOPE.
• University of Pennsylvania Perelman School of Medicine: Major medical school with established pharmacoepidemiology and health services research training. Comparable to HOPE in producing HEOR-trained graduates, with stronger brand recognition and larger research footprint.
• Harvard T.H. Chan School of Public Health - Department of Health Policy: Premier school of public health offering graduate degrees and research in health economics, policy, and outcomes. Comparable as a leading academic producer of HEOR-trained graduates, though broader in scope than HOPE's specialized MS program.

Direct peers

• USC Leonard D. Schaeffer Center for Health Policy & Economics: University-based research and training center focused on health economics, policy, and outcomes research. Directly comparable to Rutgers HOPE as an academic hub producing HEOR research and training graduate talent for the pharmaceutical and payer industries.
• University of Maryland School of Pharmacy - PATIENTS Program: Pharmacy-school research and training program focused on real-world evidence, patient-centered outcomes, and health economics. Comparable to HOPE as an academic-anchored HEOR and RWE training center with industry collaboration.
• Duke-Margolis Health Policy Center: University-based center producing health policy, economics, and real-world evidence research with industry and government engagement. Comparable to HOPE in mission and in training graduate-level HEOR and policy talent.
• University of Washington CHOICE Institute: Pharmacy-school-based institute focused on health economics, outcomes research, and pharmacoeconomics training. Directly comparable to HOPE as a pharmacy-anchored HEOR training and research center offering graduate degrees and industry fellowships.
• Brigham and Women's Hospital Division of Pharmacoepidemiology: Hospital-based pharmacoepidemiology research and training group affiliated with Harvard. Comparable to HOPE in delivering HEOR and pharmacoepidemiology training through industry partnerships and graduate programs.
• University of Illinois at Chicago College of Pharmacy: Pharmacy school with active health economics, outcomes research, and pharmacoepidemiology training programs. Comparable to HOPE as a pharmacy-anchored academic program producing HEOR graduates for pharma and payer employers.
• University of Minnesota PRIME Institute: College of Pharmacy institute delivering research and graduate training in pharmaceutical economics, policy, and outcomes. Closely comparable to HOPE's pharmacy-school-anchored HEOR mission and industry-linked fellowship model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rutgershope

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rutgers HOPE: Health Outcomes, Policy, & Economics Program